{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:45:38Z","timestamp":1790063138064,"version":"4.0.1"},"reference-count":37,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2017,4,12]],"date-time":"2017-04-12T00:00:00Z","timestamp":1491955200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Focal segmental glomerulosclerosis (FSGS) represents the most common primary glomerular disease responsible for the development of end-stage renal disease (ESRD) in the United States (US). The disease progresses from podocyte injury to chronic kidney disease (CKD), ultimately leading to total nephron degeneration. Extensive basic science research has been conducted to unwind the mechanisms of FSGS and, with those insights, understand major contributors of CKD in general. As a result, several putative molecules and pathways have been studied, all implicated in the disease; some serve, in addition, as early biomarkers. The ongoing research is currently focusing on understanding how these molecules and pathways can interplay and be utilized as potential diagnostic and therapeutic targets. Among these molecules, the soluble urokinase plasminogen activating receptor (suPAR) has been studied in detail, both clinically and from a basic science perspective. By now, it has emerged as the earliest and most robust marker of future CKD. Other circulating factors harming podocytes include anti-CD40 auto-antibody and possibly cardiotrophin-like cytokine factor-1. Understanding these factors will aid our efforts to ultimately cure FSGS and possibly treat a larger portion of CKD patients much more effectively.<\/ns4:p>","DOI":"10.12688\/f1000research.10510.1","type":"journal-article","created":{"date-parts":[[2017,4,12]],"date-time":"2017-04-12T05:40:07Z","timestamp":1491975607000},"page":"466","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Unwinding focal segmental glomerulosclerosis"],"prefix":"10.12688","volume":"6","author":[{"given":"Vasil","family":"Peev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunsil","family":"Hahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-6276","authenticated-orcid":false,"given":"Jochen","family":"Reiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2017,4,12]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"621-31","DOI":"10.1016\/S0272-6386(97)90485-6","article-title":"Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976\u20131979 and 1995\u20131997.","volume":"30","author":"M Haas","year":"1997","journal-title":"Am J Kidney Dis."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"815-25","DOI":"10.1053\/j.ajkd.2004.07.008","article-title":"Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States.","volume":"44","author":"C Kitiyakara","year":"2004","journal-title":"Am J Kidney Dis."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"898-904","DOI":"10.1111\/j.1523-1755.2004.00833.x","article-title":"Clinicopathologic correlations of renal pathology in Spain.","volume":"66","author":"F Rivera","year":"2004","journal-title":"Kidney Int."},{"key":"ref-4","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.7255.1","article-title":"Podocytes [version 1; referees: 2 approved].","volume":"5","author":"J Reiser","year":"2016","journal-title":"F1000Res."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"158-73","DOI":"10.1038\/nrneph.2014.1","article-title":"The emergence of the glomerular parietal epithelial cell.","volume":"10","author":"S Shankland","year":"2014","journal-title":"Nat Rev Nephrol."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"443-56","DOI":"10.1016\/S0272-6386(89)80001-0","article-title":"Pathogenesis and significance of nonprimary focal and segmental glomerulosclerosis.","volume":"13","author":"H Rennke","year":"1989","journal-title":"Am J Kidney Dis."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"3965-80","DOI":"10.1172\/JCI58552","article-title":"CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival.","volume":"121","author":"S Yaddanapudi","year":"2011","journal-title":"J Clin Invest."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"2095-104","DOI":"10.1172\/JCI32022","article-title":"Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease.","volume":"117","author":"S Sever","year":"2007","journal-title":"J Clin Invest."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"931-8","DOI":"10.1038\/nm.1857","article-title":"The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A.","volume":"14","author":"C Faul","year":"2008","journal-title":"Nat Med."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"1012-22","DOI":"10.1016\/j.kint.2016.06.035","article-title":"Cathepsin L is crucial for the development of early experimental diabetic nephropathy.","volume":"90","author":"M Garsen","year":"2016","journal-title":"Kidney Int."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"878-83","DOI":"10.1056\/NEJM199604043341402","article-title":"Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis.","volume":"334","author":"V Savin","year":"1996","journal-title":"N Engl J Med."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"1648-9","DOI":"10.1056\/NEJMc1202500","article-title":"Resolution of recurrent focal segmental glomerulosclerosis after retransplantation.","volume":"366","author":"L Gallon","year":"2012","journal-title":"N Engl J Med."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"693-702","DOI":"10.1083\/jcb.108.2.693","article-title":"Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate.","volume":"108","author":"R Picone","year":"1989","journal-title":"J Cell Biol."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"1655-63","DOI":"10.1038\/sj.emboj.7600635","article-title":"Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.","volume":"24","author":"P Llinas","year":"2005","journal-title":"EMBO J."},{"key":"ref-15","doi-asserted-by":"crossref","first-page":"467-74","DOI":"10.1002\/j.1460-2075.1990.tb08132.x","article-title":"Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis.","volume":"9","author":"A Roldan","year":"1990","journal-title":"EMBO J."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"100-6","DOI":"10.1038\/nm.4242","article-title":"Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease.","volume":"23","author":"E Hahm","year":"2017","journal-title":"Nat Med."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"55-63","DOI":"10.1038\/nm1696","article-title":"Modification of kidney barrier function by the urokinase receptor.","volume":"14","author":"C Wei","year":"2008","journal-title":"Nat Med."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"952-60","DOI":"10.1038\/nm.2411","article-title":"Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.","volume":"17","author":"C Wei","year":"2011","journal-title":"Nat Med."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"1662-8","DOI":"10.1681\/ASN.2013040425","article-title":"Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice.","volume":"25","author":"D Cathelin","year":"2014","journal-title":"J Am Soc Nephrol."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"564-74","DOI":"10.1038\/ki.2014.346","article-title":"A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease.","volume":"87","author":"J Spinale","year":"2015","journal-title":"Kidney Int."},{"key":"ref-21","doi-asserted-by":"publisher","DOI":"10.1038\/srep13647","article-title":"Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes.","volume":"5","author":"M Alfano","year":"2015","journal-title":"Sci Rep."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"256ra136","DOI":"10.1126\/scitranslmed.3008538","article-title":"A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation.","volume":"6","author":"M Delville","year":"2014","journal-title":"Sci Transl Med."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"656-9","DOI":"10.1126\/science.1121143","article-title":"Structure of human urokinase plasminogen activator in complex with its receptor.","volume":"311","author":"Q Huai","year":"2006","journal-title":"Science."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"2593-7","DOI":"10.1097\/TP.0000000000000914","article-title":"Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte \u03b23-integrin Activation.","volume":"99","author":"O Staeck","year":"2015","journal-title":"Transplantation."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"2051-9","DOI":"10.1681\/ASN.2012030302","article-title":"Circulating suPAR in two cohorts of primary FSGS.","volume":"23","author":"C Wei","year":"2012","journal-title":"J Am Soc Nephrol."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"366-72","DOI":"10.1038\/ki.2013.55","article-title":"Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis.","volume":"84","author":"J Huang","year":"2013","journal-title":"Kidney Int."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"1916-25","DOI":"10.1056\/NEJMoa1506362","article-title":"Soluble Urokinase Receptor and Chronic Kidney Disease.","volume":"373","author":"S Hayek","year":"2015","journal-title":"N Engl J Med."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"636-40","DOI":"10.1038\/ki.2013.505","article-title":"The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis.","volume":"85","author":"B Meijers","year":"2014","journal-title":"Kidney Int."},{"key":"ref-29","doi-asserted-by":"publisher","DOI":"10.1038\/srep40627","article-title":"Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus.","volume":"7","author":"M Guthoff","year":"2017","journal-title":"Sci Rep."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"239-247","DOI":"10.1016\/j.ekir.2016.11.004","article-title":"Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) and Impaired Kidney Function in the Population-based Malm\u00f6 Diet and Cancer Study.","volume":"2","author":"C Schulz","year":"2017","journal-title":"Kidney Int Rep."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"474-83","DOI":"10.1002\/biof.62","article-title":"CD40\/CD40L signaling and its implication in health and disease.","volume":"35","author":"A Chatzigeorgiou","year":"2009","journal-title":"Biofactors."},{"key":"ref-32","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3765608","article-title":"Circulating Permeability Factors in Primary Focal Segmental Glomerulosclerosis: A Review of Proposed Candidates.","volume":"2016","author":"E K\u00f6nigshausen","year":"2016","journal-title":"Biomed Res Int."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"708-15","DOI":"10.1093\/ckj\/sfv090","article-title":"A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues.","volume":"8","author":"T Wada","year":"2015","journal-title":"Clin Kidney J."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"2115-21","DOI":"10.2215\/CJN.03800609","article-title":"Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis.","volume":"5","author":"E McCarthy","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"key":"ref-35","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/714964","article-title":"Renal and Hematological Effects of CLCF-1, a B-Cell-Stimulating Cytokine of the IL-6 Family.","volume":"2015","author":"V Savin","year":"2015","journal-title":"J Immunol Res."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"384-98","DOI":"10.1016\/j.trsl.2015.03.002","article-title":"Janus kinase 2\/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier.","volume":"166","author":"M Sharma","year":"2015","journal-title":"Transl Res."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"601-9","DOI":"10.1038\/nm.3843","article-title":"Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models.","volume":"21","author":"M Schiffer","year":"2015","journal-title":"Nat Med."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/6-466\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/6-466\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/6-466\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T11:16:07Z","timestamp":1553253367000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/6-466\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,12]]},"references-count":37,"URL":"https:\/\/doi.org\/10.12688\/f1000research.10510.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.11328.r21621","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.11328.r21622","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.11328.r21623","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,12]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/6-466\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.11328.r21623, Vivekanand Jha, The George Institute for Global Health, New Delhi, India, 12 Apr 2017, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/6-466\/v1#referee-response-21623","order":0,"name":"referee-response-21623","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.11328.r21622, Johan van der Vlag, Radboud University Medical Center, Nijmegen, The Netherlands, 12 Apr 2017, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/6-466\/v1#referee-response-21622","order":1,"name":"referee-response-21622","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.11328.r21621, Kirk Campbell, Icahn School of Medicine at Mount Sinai, New York, USA, 12 Apr 2017, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/6-466\/v1#referee-response-21621","order":2,"name":"referee-response-21621","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Data associated with the article are available under the terms of the Creative Commons Zero \"No rights reserved\" data waiver (CC0 1.0 Public domain dedication).","order":0,"name":"copyright-info","label":"Copyright"}]}}